一种理解癌症免疫治疗时代种族差异的生物心理社会模型。
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy.
机构信息
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
出版信息
Trends Cancer. 2023 Jan;9(1):6-8. doi: 10.1016/j.trecan.2022.10.002. Epub 2022 Oct 22.
Abstract
The approval and wide uptake of immune checkpoint inhibitors (ICIs) in oncology practice raise the concerns of possibly worsened racial disparities in cancer treatment due to biological and psychosocial reasons. We propose a multilevel biopsychosocial model to understand the opportunities and challenges to racial disparities in the era of cancer immunotherapy.
摘要
免疫检查点抑制剂 (ICI) 在肿瘤学实践中的广泛批准和采用引起了人们的担忧，即由于生物学和社会心理原因，癌症治疗中的种族差异可能会恶化。我们提出了一个多层次的生物心理社会模型，以了解癌症免疫治疗时代种族差异的机遇和挑战。
相似文献
1
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy.
Trends Cancer. 2023 Jan;9(1):6-8. doi: 10.1016/j.trecan.2022.10.002. Epub 2022 Oct 22.
2
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Curr Opin Pharmacol. 2020 Oct;54:1-10. doi: 10.1016/j.coph.2020.06.004. Epub 2020 Jun 30.
3
Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.
J Immunother Cancer. 2018 Jan 29;6(1):6. doi: 10.1186/s40425-018-0317-y.
4
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Clin Transl Oncol. 2021 Dec;23(12):2415-2430. doi: 10.1007/s12094-021-02659-w. Epub 2021 Jun 14.
5
Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Cancer Treat Rev. 2019 Mar;74:49-60. doi: 10.1016/j.ctrv.2018.08.006. Epub 2018 Aug 20.
6
Using the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments.
Semin Neurol. 2022 Apr;42(2):80-87. doi: 10.1055/s-0041-1742145. Epub 2022 Feb 3.
7
Targeting protein kinases benefits cancer immunotherapy.
Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188738. doi: 10.1016/j.bbcan.2022.188738. Epub 2022 Jun 2.
8
HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.
Front Immunol. 2021 Jun 30;12:698677. doi: 10.3389/fimmu.2021.698677. eCollection 2021.
9
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
Oncologist. 2019 Feb;24(Suppl 1):S11-S20. doi: 10.1634/theoncologist.2019-IO-S1-s03.
10
Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIm)-insights of people affected by cancer and healthcare professionals: a qualitative study protocol.
BMJ Open. 2021 May 27;11(5):e043750. doi: 10.1136/bmjopen-2020-043750.
引用本文的文献
1
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee.
J Immunother Cancer. 2025 Jun 22;13(6):e011258. doi: 10.1136/jitc-2024-011258.
2
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.
Hepatology. 2025 Mar 28. doi: 10.1097/HEP.0000000000001328.
3
Receiving immunotherapy for the treatment of advanced renal cell carcinoma is associated with higher burden of illness, coagulopathy, cardiac arrhythmia, and disparities.
Support Care Cancer. 2025 Mar 15;33(4):285. doi: 10.1007/s00520-025-09353-5.
4
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.
JAMA Netw Open. 2025 Feb 3;8(2):e2460243. doi: 10.1001/jamanetworkopen.2024.60243.
5
Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.
J Clin Med. 2025 Jan 29;14(3):879. doi: 10.3390/jcm14030879.
6
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors.
JCO Oncol Pract. 2025 Mar;21(3):408-417. doi: 10.1200/OP.24.00033. Epub 2024 Aug 22.
本文引用的文献
1
The distinct impacts of race and genetic ancestry on health.
Nat Med. 2022 May;28(5):890-893. doi: 10.1038/s41591-022-01796-1.
2
Cancer statistics, 2022.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB).
J Immunother. 2022;45(2):132-137. doi: 10.1097/CJI.0000000000000400.
4
Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes.
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-13. doi: 10.1200/EDBK_323523.
5
Biological Aspects of Cancer Health Disparities.
Annu Rev Med. 2021 Jan 27;72:229-241. doi: 10.1146/annurev-med-070119-120305.
6
Race and Genetic Ancestry in Medicine - A Time for Reckoning with Racism.
N Engl J Med. 2021 Feb 4;384(5):474-480. doi: 10.1056/NEJMms2029562. Epub 2021 Jan 6.
7
Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion.
J Natl Cancer Inst. 2021 Aug 2;113(8):1036-1043. doi: 10.1093/jnci/djaa215.
8
Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer.
Cancer Immunol Res. 2019 Sep;7(9):1384-1389. doi: 10.1158/2326-6066.CIR-18-0564.
9
Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:3-10. doi: 10.1200/EDBK_100021. Epub 2019 May 17.
10
Cancer statistics for African Americans, 2019.
CA Cancer J Clin. 2019 May;69(3):211-233. doi: 10.3322/caac.21555. Epub 2019 Feb 14.
Zotero 插件